Cisapride accelerates gastric emptying and mouth-to-caecum transit of a barium meal.
Cisapride (R 51 619) is a newly synthesized compound, which facilitates the release of acetylcholine in the myenteric plexus of the gut. Its effect on gastric emptying of a barium meal was evaluated in 84 patients under randomized, double-blind conditions. Two oral doses (5 mg and 10 mg) of cisapride were compared with a placebo, and two intravenous doses (4 mg and 8 mg) with a placebo and with 10 mg metoclopramide. All doses of cisapride and metoclopramide were significantly superior to placebo in accelerating gastric emptying, intensifying antral contractions and shortening the mouth-to-caecum transit time. The effects of 8 mg cisapride and 10 mg metoclopramide given intravenously were comparable.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001466:Barium Sulfate / Q000378:metabolism*; D020117:Cisapride; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D008875:Middle Aged; D010528:Peristalsis / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*
D005765:Gastrointestinal Agents; D010880:Piperidines; D001466:Barium Sulfate; D008787:Metoclopramide; D020117:Cisapride